Cargando…

Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?

BACKGROUND: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study...

Descripción completa

Detalles Bibliográficos
Autores principales: Gur, Ali, Dikici, Bünyamin, Nas, Kemal, Bosnak, Mehmet, Haspolat, Kenan, Sarac, Aysegul Jale
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242225/
https://www.ncbi.nlm.nih.gov/pubmed/16171525
http://dx.doi.org/10.1186/1471-230X-5-30
_version_ 1782125617370628096
author Gur, Ali
Dikici, Bünyamin
Nas, Kemal
Bosnak, Mehmet
Haspolat, Kenan
Sarac, Aysegul Jale
author_facet Gur, Ali
Dikici, Bünyamin
Nas, Kemal
Bosnak, Mehmet
Haspolat, Kenan
Sarac, Aysegul Jale
author_sort Gur, Ali
collection PubMed
description BACKGROUND: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B treated with IFN-alpha. METHODS: BMD, levels of parathyroid hormone (PTH), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), calcium, alkaline phosphates (ALP), cytokines as TNF-alpha, interleukin (IL)-1(β), IL-2r, IL-6, and IL-8 were studied in 54 children with chronic hepatitis B (4–15 years old) treated with interferon alone (n = 19) or in combination with lamivudine (n = 35) for six months and as controls in 50 age-matched healthy children. RESULTS: There was no significant difference in respect to serum IL-1(β), TNF-α and osteocalcin levels while serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p = 0.013), PTH (p = 0.029), and CTX (p = 0.021) levels were higher in children with chronic hepatitis B than in healthy controls. BMD of femur neck (p = 0.012) and trochanter (p = 0.046) in patients were higher than in healthy controls. There was a statistically significant correlation between serum IL-1(β )and osteocalcin (r = -0.355, p < 0.01); between serum IL-8 and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361, p = 0.01); between serum ALP and femur neck BMD (r = 0.303, p = 0.05), and trochanter BMD (r = 0.365, p = 0.01); between spine BMD and IL-2R (r = -0.330, p < 0.05). CONCLUSION: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine than in healthy children. High femur BMD measurements found in patients may suggest that IFN-alpha therapy in children with chronic hepatitis B could contribute indirectly to prevent from hip osteoporosis. Additionally, further investigations on effects of IFN-alpha for bone structure in children should be performed in the future.
format Text
id pubmed-1242225
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-12422252005-10-06 Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? Gur, Ali Dikici, Bünyamin Nas, Kemal Bosnak, Mehmet Haspolat, Kenan Sarac, Aysegul Jale BMC Gastroenterol Research Article BACKGROUND: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B treated with IFN-alpha. METHODS: BMD, levels of parathyroid hormone (PTH), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), calcium, alkaline phosphates (ALP), cytokines as TNF-alpha, interleukin (IL)-1(β), IL-2r, IL-6, and IL-8 were studied in 54 children with chronic hepatitis B (4–15 years old) treated with interferon alone (n = 19) or in combination with lamivudine (n = 35) for six months and as controls in 50 age-matched healthy children. RESULTS: There was no significant difference in respect to serum IL-1(β), TNF-α and osteocalcin levels while serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p = 0.013), PTH (p = 0.029), and CTX (p = 0.021) levels were higher in children with chronic hepatitis B than in healthy controls. BMD of femur neck (p = 0.012) and trochanter (p = 0.046) in patients were higher than in healthy controls. There was a statistically significant correlation between serum IL-1(β )and osteocalcin (r = -0.355, p < 0.01); between serum IL-8 and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361, p = 0.01); between serum ALP and femur neck BMD (r = 0.303, p = 0.05), and trochanter BMD (r = 0.365, p = 0.01); between spine BMD and IL-2R (r = -0.330, p < 0.05). CONCLUSION: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine than in healthy children. High femur BMD measurements found in patients may suggest that IFN-alpha therapy in children with chronic hepatitis B could contribute indirectly to prevent from hip osteoporosis. Additionally, further investigations on effects of IFN-alpha for bone structure in children should be performed in the future. BioMed Central 2005-09-19 /pmc/articles/PMC1242225/ /pubmed/16171525 http://dx.doi.org/10.1186/1471-230X-5-30 Text en Copyright © 2005 Gur et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Gur, Ali
Dikici, Bünyamin
Nas, Kemal
Bosnak, Mehmet
Haspolat, Kenan
Sarac, Aysegul Jale
Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
title Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
title_full Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
title_fullStr Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
title_full_unstemmed Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
title_short Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
title_sort bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis b: does interferon therapy prevent from osteoporosis?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242225/
https://www.ncbi.nlm.nih.gov/pubmed/16171525
http://dx.doi.org/10.1186/1471-230X-5-30
work_keys_str_mv AT gurali bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis
AT dikicibunyamin bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis
AT naskemal bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis
AT bosnakmehmet bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis
AT haspolatkenan bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis
AT saracayseguljale bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis